Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Harvard Bioscience (HBIO) over the last 16 years, with Q3 2025 value amounting to $324000.0.

  • Harvard Bioscience's Share-based Compensation fell 6923.08% to $324000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 5049.36%. This contributed to the annual value of $4.3 million for FY2024, which is 1320.0% down from last year.
  • Harvard Bioscience's Share-based Compensation amounted to $324000.0 in Q3 2025, which was down 6923.08% from $472000.0 recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Share-based Compensation ranged from a high of $1.4 million in Q4 2023 and a low of $324000.0 during Q3 2025
  • Its 5-year average for Share-based Compensation is $1.0 million, with a median of $1.0 million in 2024.
  • In the last 5 years, Harvard Bioscience's Share-based Compensation surged by 5136.54% in 2021 and then plummeted by 6923.08% in 2025.
  • Over the past 5 years, Harvard Bioscience's Share-based Compensation (Quarter) stood at $1.0 million in 2021, then decreased by 2.23% to $1.0 million in 2022, then surged by 36.83% to $1.4 million in 2023, then crashed by 30.46% to $961000.0 in 2024, then crashed by 66.29% to $324000.0 in 2025.
  • Its Share-based Compensation was $324000.0 in Q3 2025, compared to $472000.0 in Q2 2025 and $600000.0 in Q1 2025.